Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
BioSpace
The FDA has granted a three-month extension for Capricor Therapeutics' Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication.
pharminent
August 24, 2026 (Last updated: September 1, 2026)
BioSpace
The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication.